To validate the significance of our findings for human CML, we addressed whether CD8+ CTLs can kill CD34+CD38– CML stem/progenitor cells derived from newly diagnosed chronic phase CML patients and whether this effect can be reverted in the presence of Tregs (Supplemental Table 2). Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.